Skip to main content

Table 1 Patient characteristics of the entire cohort

From: Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Characteristics No. of patients (N = 721) %
Breast cancer type
 Invasive ductal 664 92
 Invasive lobular 9 1
 Mixed ductal/lobular 14 2
 Breast cancer, NOSa 16 2
 Other 18 3
Age, years
 21–40 154 21
 41–60 449 63
 > 60 118 16
Race
 White 423 59
 Hispanic 136 19
 Black 109 15
 Asian 45 6
 Other 8 1
Menopausal status
 Unknown 1 0
 Premenopausal 314 44
 Pregnant 3 0
 Perimenopausal 14 2
 Postmenopausal 389 54
Clinical stage
 IIA 292 41
 IIB 153 21
 IIIA 78 11
 IIIB 66 9
 IIIC 132 19
Estrogen receptor status
 Unknown 15 2
 Negative 454 63
 Positive 252 35
Progesterone receptor status
 Unknown 19 3
 Negative 526 73
 Positive 176 24
HER2 status
 Negative 286 40
 Positive 312 43
 Equivocal 123 17
Tumor subtype
 Unknown 18 3
 HR 157 22
 TN 236 33
HER2-amplified 310 43
 HR+ 128 41
 HR− 178 57
 Unknown HR 4 1
Neoadjuvant chemotherapy
 A no T 56 8
 A + T 367 51
 AT + HER2 227 31
 PC 71 10
HER2+ patient regimens
 HER2-containing regimen 247 80
 No HER2 60 20
Length of NACT therapy
 0–4 months 64 9
 4 & 7 months 570 79
 7 months 87 12
Neoadjuvant hormonal therapy
 Yes 12 0
 No 715 100
Neoadjuvant radiation therapy
 Yes 1 0
 No 720 100
Adjuvant chemotherapy
 Yes 196 27
 No 525 73
Adjuvant endocrine therapy
 Yes 261 36
 No 460 64
Adjuvant radiation therapy
 Yes 559 78
 No 162 22
Outcomes
 Progression 63 9
 Death (any cause) 62 9
 Progression + death 40 6
 Death without progression 22 3
Site of metastasis
 Distant first 41 65
  Brain-only 13 32
  Bone-only 4 10
  Liver-only 4 10
  Lung-only 3 7
  Mixed/other 17 41
 Local first 11 17
  Chest wall-only 1 9
  Ipsilateral breast-only 10 91
 Both local and distant 11 17
  Concurrenta 6 55
  Sequential 5 45
  1. Abbreviations: NOS Not otherwise specified, HR Hormone receptor; TN Triple-negative breast cancer, A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC Provider choice, NACT Neoadjuvant chemotherapy
  2. aConcurrent local and distant metastases were diagnosed within 1 month of each other
\